November 9, 2010
IntegenX Inc. (IXI), a developer of automated DNA and RNA based sample preparation systems today announced that it has been awarded four grants totaling $976,000 under the Qualifying Therapeutic Discovery Project Program (QTDP). The IntegenX programs focus on developing platforms for DNA sample preparation, next-generation sequencing library preparation, and sample-to-answer analysis of human genotypes.
“We are pleased to receive federal recognition that our platforms have the potential for impacting the development of therapeutics, molecular diagnostics, and discovery of genetic markers that will improve outcomes for patients,” said Dr. Stevan Jovanovich, CEO and President of IntegenX. “These awards provide IntegenX with additional support to continue development of our products and to accelerate advancing them to the market.”
The QTDP is provided under Section 48D of the Internal Revenue Code, enacted as part of the Patient Protection and Affordable Health Care Act of 2010. Qualifying projects had to show potential to produce new therapies, reduce long-term health care costs, or significantly advance the goal of curing cancer within the next 30 years. Preference was given to projects that showed the greatest potential to create and sustain high-quality, high-paying jobs in the U.S. and advance the country’s competitiveness in the fields of life, biological, and medical sciences.